The policy lag tax: when the cost of waiting is greater than the cost of action

Australia's health debates tend to revolve around familiar themes: funding pressures, workforce shortages, and access to care. These are important concerns. Yet there is another issue, less visible but increasingly consequential, that rarely receives the same attention.

It is time.

Health systems are remarkably good at measuring the cost of treatment. They are less adept at measuring the cost of waiting for policy decisions.

Delay is usually treated as administrative friction, an unfortunate but inevitable feature of careful governance. Assessment takes time. Consultation matters. Evidence must be scrutinised, budgets balanced and competing priorities weighed. In a publicly funded health system, caution is often not merely prudent but necessary.

And yet delay is not neutral.

When policy and regulatory systems move too slowly, they impose costs of their own. These costs are rarely itemised in budget papers or annual reports. They do not appear neatly on balance sheets. But they are real nonetheless.

The price we pay for delayed decision-making

I describe this as the policy lag tax, the cumulative human, economic and system cost created when decision-making struggles to keep pace with progress.

The phrase is not intended as an indictment of Australia's institutions. On the contrary, Australians rightly place considerable trust in their health system and regulators. Rigour matters. Safety matters. Evidence matters.

But medicine has entered an age of accelerating possibility, while policy often still moves at analogue speed.

New therapies, precision medicine, advanced diagnostics, digital technologies and artificial intelligence are reshaping clinical care at a pace that would have seemed improbable only a decade ago. The challenge is no longer merely scientific discovery. It is whether institutions designed for an earlier era can adapt to a faster one.

This matters first because delay carries a human cost.

For policymakers, time can feel procedural. For patients, it is rarely experienced that way.

Waiting for access to a medicine, a diagnostic pathway or a policy decision is not simply a bureaucratic interval. It may mean prolonged symptoms, deteriorating disease or lost therapeutic opportunity. Particularly in serious or progressive illness, time itself becomes clinically significant.

Spinal muscular atrophy: when delay costs lives

The policy lag tax becomes most visible when medicine and time collide.

Few examples illustrate the policy lag tax more clearly than spinal muscular atrophy (SMA). SMA effects one in 10 000 births and, before disease-modifying therapies transformed what had long been viewed as an inexorable diagnosis, SMA was the leading genetic cause of death for Australian babies. 

The arrival of disease-modifying therapies changed more than treatment options. It changed the meaning of diagnosis itself. A heel prick test was no longer simply diagnostic; it became a gateway to therapeutic opportunity in a disease where time could shape whether a child survived or the degree of disability they would later live with.

SMA exposed the uncomfortable intersection between medical possibility and policy delay. As clinicians, families and policymakers debated newborn screening for SMA, the question was not merely whether the condition could be identified, but whether it could be identified quickly enough for treatment to matter.

The debate also exposed an uncomfortable reality. Adding SMA to the newborn screening panel would cost only around $10 per heel prick test, yet it became entangled in prolonged health technology assessment (HTA) and jurisdictional delay even as treatment windows for Australian babies narrowed. The administrative cost was measured in dollars; the cost of waiting could be measured in disability and death.

Several states ultimately moved ahead, and funded screening themselves, before national arrangements were settled. Their actions reflected a growing recognition that policy time and clinical time did not move at the same speed. That states felt compelled to assume what many regarded as a national responsibility spoke to a widening gap between clinical urgency and Commonwealth process.

The significance of SMA therefore lies beyond any single disease. It illustrates a broader challenge increasingly confronting modern health systems: whether we adequately account for the cost of waiting alongside the cost of action.

Delay is not unique to rare diseases. Across many areas of healthcare, patients encounter delays that are often treated as operational rather than policy concerns such as delays in assessment pathways, reimbursement decisions, implementation of evidence, workforce responses or adoption of innovation. Each case differs, and not every delay is avoidable or inappropriate. But the cumulative effect deserves greater scrutiny.

The economic dimension of the policy lag tax

Australia frequently debates productivity, labour participation and the sustainability of public expenditure, often treating health principally as a cost centre. Yet poor health and delayed intervention carry economic consequences of their own.

Untreated or inadequately managed illness may reduce workforce participation, increase absenteeism and generate higher downstream costs elsewhere in the system. Delayed diagnosis and treatment can mean greater complexity, more intensive care and higher health and welfare utilisation later.

The assumption that delay conserves resources is therefore not always correct.

Sometimes it does. At other times, delay merely shifts cost from one ledger to another — from prevention to acute care, from Commonwealth to state systems, or from today's budget to tomorrow's.

Australia rightly takes pride in its medical research capability and clinical expertise. But innovation does not end with discovery. A nation's ability to evaluate, adopt and implement advances matters equally.

If clinicians, researchers and innovators increasingly perceive Australia as characterised by prolonged uncertainty or slow translation from evidence to implementation, there may be broader consequences. Research investment, clinical trial attractiveness and the willingness to introduce novel models of care may all be affected.

None of this is an argument for abandoning rigour or embracing speed for its own sake.

Fast decisions are not necessarily good decisions. Public systems exist precisely because difficult judgments must be made carefully and fairly. Nor should timeliness become a proxy for automatic approval or unrestricted funding.

But neither should caution become confused with inertia.

Balancing caution and capability

The uncomfortable reality is that health systems often devote substantial effort to measuring expenditure while paying far less attention to measuring delay. Yet timeliness is not merely an operational consideration. Increasingly, it may be a policy outcome in its own right.

This raises difficult but necessary questions.

Are our assessment pathways appropriately sequenced? Can duplication and fragmentation be reduced? Do current processes sufficiently account for the cost of waiting alongside the cost of treatment? And are we adequately recognising that responsiveness, alongside safety and equity, is itself a feature of high-performing health systems?

Australia's health system remains one of our great institutional achievements. Preserving public trust in it matters enormously.

But trust is sustained not only through caution.

It is sustained through capability.

The greatest risk to modern health systems may not always be reckless decision-making.

Increasingly, it is institutional hesitation mistaken for prudence.

Vincent So is Chief Executive Officer of the Thoracic Society of Australia and New Zealand and has worked across healthcare, biopharmaceuticals, investment banking, government and public policy.